Date: 2013-07-16
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France - Austria) Boehringer Ingelheim (Germany)
Therapeutic area: Veterinary diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: * On July 16, 2013, Valneva has announced that it has signed an EB66® cell line research license agreement with Boehringer Ingelheim for the development of animal health vaccines. This non-exclusive agreement also
includes a commercial option for future marketed products. Boehringer Ingelheim has been a licensee to the EB66®cell line since 2010 and is now expanding its research programs to investigate additional viruses in EB66®cells. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
